MiNK Therapeutics, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
MiNK Therapeutics, Inc. (INKT) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $630.38 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-13
- MiNK Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $630.38K, a 10617.14% increase year-over-year.
- MiNK Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $8.08K, a 68.08% decline year-over-year.
- MiNK Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-03-31 was $5.88K, a 78.24% decline year-over-year.
- MiNK Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2024-09-30 was $25.50K, a 22.99% decline year-over-year.
- MiNK Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $13.96K, a 86.93% decline from fiscal 2024.
- MiNK Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $106.83K, a 19.03% decline from fiscal 2023.
- MiNK Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $131.93K, a 37.41% increase from fiscal 2022.
- MiNK Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $96.01K, a 22.73% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-03-31 | $630.38K 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $13.96K 10-K · filed 2026-03-31 | |||
| 2025-06-30 | $8.08K 10-Q · filed 2026-08-13 | $13.96K derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $5.88K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $106.83K 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $25.50K 10-Q · filed 2025-11-14 | $50.81K derived: sum of 2 quarters · filed 2025-11-14 | $77.85K derived: sum of 3 quarters · filed 2025-11-14 | |
| 2024-06-30 | $25.31K 10-Q · filed 2025-11-14 | $52.35K derived: sum of 2 quarters · filed 2025-11-14 | ||
| 2024-03-31 | $27.03K 10-Q · filed 2025-11-14 | |||
| 2023-12-31 | $131.93K 10-K · filed 2025-03-18 | |||
| 2023-09-30 | $33.11K 10-Q · filed 2024-11-14 | $66.46K derived: sum of 2 quarters · filed 2024-11-14 | $99.79K derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $33.35K 10-Q · filed 2024-11-14 | $66.67K derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-03-31 | $33.33K 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $96.01K 10-K · filed 2024-03-21 | |||
| 2022-09-30 | $27.02K 10-Q · filed 2023-11-14 | $30.91K derived: sum of 2 quarters · filed 2023-11-14 | $74.64K derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-06-30 | $3.89K 10-Q · filed 2023-11-14 | $47.62K derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2022-03-31 | $43.73K 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | $124.26K 10-K · filed 2023-03-24 | |||
| 2021-09-30 | $21.60K 10-Q · filed 2022-11-03 | $72.81K derived: sum of 2 quarters · filed 2022-11-03 | $92.76K derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | $51.21K 10-Q · filed 2022-11-03 | $71.16K derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | $19.95K 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $86.46K 10-K · filed 2022-03-18 | |||
| 2020-09-30 | $10.41K 10-Q · filed 2021-11-29 | $23.04K derived: sum of 2 quarters · filed 2021-11-29 | $52.57K derived: sum of 3 quarters · filed 2021-11-29 | |
| 2020-06-30 | $12.63K 10-Q · filed 2021-11-29 | $42.16K derived: sum of 2 quarters · filed 2021-11-29 | ||
| 2020-03-31 | $29.53K 10-Q · filed 2021-11-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |